Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2017-11-15 Interim / Quarterly Rep…
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
UNAUDITED RESULTS FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2017
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Results For the Nine Months Ended 30 September 2017' and contains detailed unaudited consolidated financial results, including revenue, profit, segment information, earnings per share, and business review for the nine months ended 30 September 2017. It includes comprehensive financial statements and analysis for a period shorter than a full fiscal year. The document is not a brief announcement but a full financial report with substantive financial data and management commentary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). 9M 2017
2017-11-15 English
VOLUNTARY ANNOUNCEMENT - THE GROUP'S "HA121-28" AND "ALPROSTADIL LIPOSOME INJECTION" WERE GRANTED CLINICAL TRIAL APPROVALS
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding clinical trial approvals granted by the China Food and Drug Administration (CFDA) for two drugs developed by the company. It contains no financial data, no detailed financial statements, no management discussion of financial results, nor any regulatory certifications or voting results. The document is relatively short (3375 characters) and serves as a public announcement of a significant development related to the company's drug pipeline. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing or certification. It is not related to capital changes, mergers, or board changes. The content is clearly an announcement of a clinical trial approval, which is a material event but not a financial report. Given the nature and length, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2017-11-05 English
DATE OF BOARD MEETING
Regulatory Filings Classification · 95% confidence The document is a short announcement from CSPC Pharmaceutical Group Limited stating the date of a board meeting to approve the third quarterly results for the nine months ended 30 September 2017. It does not contain any financial data or detailed report content but merely announces the upcoming board meeting and the agenda to approve quarterly results. The document length is only 1294 characters, which is quite short and fits the pattern of an announcement rather than a full report. According to the rules, such announcements about board meetings and approval of financial results fall under Regulatory Filings (RNS) as they do not contain the actual financial statements or detailed analysis. Therefore, the correct classification is Regulatory Filings (RNS).
2017-11-03 English
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 OCTOBER 2017
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/10/2017, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised and issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and issuance activities during the month, including rights issues, placings, and repurchases. There is no financial performance data, earnings information, or management discussion. The document is a regulatory filing reporting monthly share capital movements rather than a financial report or announcement of voting results. Therefore, it fits best under the category of Share Issue/Capital Change (SHA). The document length is substantial and contains detailed data, confirming it is the report itself, not just an announcement.
2017-11-03 English
NEXT DAY DISCLOSURE RETURN
Share Issue/Capital Change Classification · 95% confidence The document is a disclosure return related to changes in issued share capital and share buybacks for a Main Board listed issuer, CSPC Pharmaceutical Group Limited. It references specific rules from the Hong Kong Stock Exchange Listing Rules (rule 13.25A and rule 10.06(4)(a)) governing disclosures of share capital changes and repurchases. The document includes detailed data on share issues, repurchases, and closing balances, as well as notes explaining the disclosure requirements. It is a regulatory disclosure filing about capital changes rather than a full financial report or announcement of results. The content fits the category of Share Issue/Capital Change announcements, which cover new share issues, stock splits, or other capital changes. The document is not an annual or interim report, earnings release, or a general regulatory filing. Therefore, the appropriate classification is Share Issue/Capital Change (SHA). The document length (6036 characters) and detailed data support this classification with high confidence.
2017-10-20 English
COMPLETION OF PLACING OF NEW SHARES UNDER GENERAL MANDATE
Capital/Financing Update Classification · 95% confidence The document is an announcement from CSPC Pharmaceutical Group Limited regarding the completion of a placing of new shares under a general mandate. It details the number of shares placed, the placing price, the proceeds, and the effects on shareholding structure. There is no financial statement or detailed financial analysis present, only information about a capital raising transaction. The document is not a full financial report, earnings release, or management discussion. It is a specific update on a financing activity related to share issuance. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 5320 characters, which is sufficient for a detailed announcement but not a full report. Hence, the classification is CAP with high confidence.
2017-10-20 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.